Fig. 3.

The jetPEI/DIG-3 could provide potent anti-A(H7N7) virus efficacy in mice. a Experimental design for evaluating antiviral efficacy of jetPEI/DIG-3 in mice. b Expression of DI-PA, DI-PB1, and DI-PB2 RNAs in mouse lungs when jetPEI/DIG-3 (5 μg per mouse), DIG-3, jetPEI/empty vector were intratracheally inoculated to mouse lungs. Three mice in each group were included. c, d Prophylactic efficacy of jetPEI/DIG-3 against A(H7N7) virus. e, f Therapeutic efficacy of jetPEI/DIG-3 against A(H7N7) virus. For prophylactic experiment, 40 μl of PBS (n = 10), zanamivir (50 μg in PBS, n = 10), jetPEI (0.7 μl in 5% glucose solution, n = 5), jetPEI/empty vector (0.7 μl/5.0 μg in 5% glucose solution, n = 10), and jetPEI/DIG-3 (0.7 μl/5.0 μg in 5% glucose solution, n = 10) were intratracheally inoculated to corresponding mice at 48 and 24 h before viral inoculation. For therapeutic experiment, PBS, zanamivir, jetPEI, jetPEI/empty vector and jetPEI/DIG-3 were intratracheally inoculated to corresponding mice at 6 and 24 h after viral inoculation. Survivals and body weight data were generated from 5 to 10 mice in each group with mean ± SD. P values were calculated by Gehan–Breslow–Wilcoxon test